Jubilant Pharmova Q2 FY27: PAT ₹56 & Rev ₹2,229 Cr

Metric	Value
Revenue	₹2,229 Cr
Net Profit (PAT)	₹56

📢 Key Event
Jubilant Pharmova reports 17% YoY revenue growth to ₹2,229 crores in Q1 FY27, with EBITDA margin down to 11.9% and PAT declining 45% to ₹56 crores.

🔄 What Changed
Revenue grew 17% YoY to ₹2,229 crores; EBITDA margin fell 385 bps to 11.9%; PAT dropped 45% to ₹56 crores; CDMO sterile injectables grew 34% YoY.

🔮 What's Next
Target doubling revenue to Rs. 13,500 crores by FY30 with >50% EBITDA margins; investing $60+ million to expand PET sites to 9 by FY28; expects EBITDA margin improvement in H2 FY27.

💡 Investor Takeaway
Revenue growth is strong but profitability is under pressure; long-term targets require margin expansion to justify growth investments.

Jubilant Pharmova reported Q1 FY27 revenue of ₹2,229 crores, up 17% YoY, driven by 19% growth in radiopharmacy and 34% surge in CDMO sterile injectables, though EBITDA margin declined to 11.9% (-385 bps YoY) due to margin pressure. Reported PAT fell 45% to ₹56 crores with margin dropping to 2.5% (-285 bps). The company targets doubling revenue to Rs. 13,500 crores by FY30 with >50% EBITDA margins, investing $60+ million to expand PET sites to 9 by FY28. US revenue dominates at 81% (95% USD-denominated), with minimal tariff risk. Key growth engines include Ruby-Fill® (26% YoY), MIBG therapy, and allergy immunotherapy (USD 2.7 Bn market by 2028).

📄 View Original Announcement (PDF)

📊 Stock Analysis — JUBLPHARMA ✨ Ask AI About This

About Jubilant Pharmova Limited (JUBLPHARMA)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹14,055.76 Cr P/E: 39.7 ROE: 5.0% ROCE: 7.4% Div Yield: 0.57%

View full JUBLPHARMA stock details →

📡 Get AI alerts when JUBLPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track JUBLPHARMA — Free

💡 Ask AI about this filing

"How will EBITDA margins reach >50% by FY30 given current 11.9%?" "What is the revenue contribution split between radiopharma and CDMO services?" "When will CMO Montreal remediation costs stop impacting margins?"

Ask AI Free →

📊 More JUBLPHARMA filings

See all JUBLPHARMA filings →

🔥 Also filed on 10 August 2026

TIMKEN Timken India Limited Financial Results DOMS DOMS Industries Limited Corporate Action HGS Hinduja Global Solutions Limited Financial Results SUNDRMFAST Sundram Fasteners Limited Financial Results AMJLAND Amj Land Holdings Limited Annual Report KANSAINER Kansai Nerolac Paints Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when JUBLPHARMA files new disclosures

Track JUBLPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track JUBLPHARMA — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd